Last reviewed · How we verify
MW032
MW032 is a monoclonal antibody targeting PD-L1 to enhance anti-tumor immune responses by blocking the interaction between PD-L1 and PD-1/B7-1.
MW032 is a monoclonal antibody targeting PD-L1 to enhance anti-tumor immune responses by blocking the interaction between PD-L1 and PD-1/B7-1. Used for Non-small cell lung cancer, Other solid tumors (under investigation).
At a glance
| Generic name | MW032 |
|---|---|
| Also known as | recombinant human anti-RANKL monoclonal antibody injection |
| Sponsor | Mabwell (Shanghai) Bioscience Co., Ltd. |
| Drug class | PD-L1 inhibitor |
| Target | PD-L1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
MW032 binds to programmed death ligand 1 (PD-L1) on tumor cells and immune cells, preventing engagement with PD-1 and B7-1 receptors on T cells. This blockade reverses T cell exhaustion and restores anti-tumor immunity, allowing the immune system to recognize and eliminate cancer cells more effectively.
Approved indications
- Non-small cell lung cancer
- Other solid tumors (under investigation)
Common side effects
- Fatigue
- Immune-related adverse events (pneumonitis, hepatitis, colitis)
- Infusion reactions
Key clinical trials
- Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma (PHASE2)
- Efficacy and Safety of MW032 and Xgeva® in Subjects With Bone Metastases From Solid Tumors (PHASE3)
- Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oophorectomy (EARLY_PHASE1)
- Comparing of the Pharmacokinetic, Pharmacodynamic, Safety and Immunogenicity of MW032 and Xgeva® in Healthy Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MW032 CI brief — competitive landscape report
- MW032 updates RSS · CI watch RSS
- Mabwell (Shanghai) Bioscience Co., Ltd. portfolio CI